A 64-year-old with PAD and diabetes underwent fem-pop stent placement and is on rivaroxaban 2.5 mg BID plus aspirin. He asks about bleeding risk. What is appropriate counseling?ABleeding risk is identical to aspirin aloneBThere is an increased bleeding risk; benefits in reducing MACE/MALE should be balanced with patient values and riskCNo need to monitor for bleedingDStop therapy after 1 month to avoid bleedingESwitch to warfarin to reduce bleeding riskCheck my answer